Eli Lilly and Co

Find Ratings Reports
LLY : NYSE : Health Care
$78.24 up 0.23 | 0.29%
Today's Range: 77.84 - 78.82
Avg. Daily Volume: 3,931,900
08/26/16 - 4:00 PM ET

Financial Analysis


LILLY (ELI) & CO's gross profit margin for the second quarter of its fiscal year 2016 has decreased when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. LILLY (ELI) & CO has average liquidity. Currently, the Quick Ratio is 1.00 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has remained unchanged from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY16 Q2 FY15
Net Sales ($mil)5404.84978.7
EBITDA ($mil)1355.01392.3
EBIT ($mil)981.31023.8
Net Income ($mil)747.7600.8


Balance Sheet Q2 FY16 Q2 FY15
Cash & Equiv. ($mil)3934.84230.9
Total Assets ($mil)36475.336036.6
Total Debt ($mil)9331.37999.4
Equity ($mil)14637.314670.3


Profitability Q2 FY16 Q2 FY15
Gross Profit Margin79.8184.3
EBITDA Margin25.0727.96
Operating Margin18.1620.56
Sales Turnover0.560.54
Return on Assets6.765.71
Return on Equity16.8414.03
Debt Q2 FY16 Q2 FY15
Current Ratio1.541.5
Debt/Capital0.390.35
Interest Expense57.250.2
Interest Coverage17.1620.39


Share Data Q2 FY16 Q2 FY15
Shares outstanding (mil)1103.841108.54
Div / share0.510.5
EPS0.710.56
Book value / share13.2613.23
Institutional Own % n/a n/a
Avg Daily Volume3969681.04459511.0

Valuation


BUY. LILLY (ELI) & CO's P/E ratio indicates a premium compared to an average of 29.72 for the Pharmaceuticals industry and a premium compared to the S&P 500 average of 25.30. To use another comparison, its price-to-book ratio of 6.02 indicates a significant premium versus the S&P 500 average of 2.83 and a significant discount versus the industry average of 20.24. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
LLY 34.39 Peers 29.72   LLY 28.27 Peers 21.39

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

LLY is trading at a premium to its peers.

 

Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

LLY is trading at a significant premium to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
LLY 19.45 Peers 15.44   LLY 0.58 Peers 0.57

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

LLY is trading at a significant premium to its peers.

 

Average. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

LLY trades at a valuation on par to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
LLY 6.02 Peers 20.24   LLY 20.20 Peers -21.30

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

LLY is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

LLY is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
LLY 4.27 Peers 12.00   LLY 5.01 Peers 5.66

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

LLY is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

LLY trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades